4.2 Article

Cell(s) of Origin of Langerhans Cell Histiocytosis

期刊

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2015.06.003

关键词

Langerhans cell histiocytosis; BRAF; MAPK signaling; Dendritic cell; Myeloid differentiation

资金

  1. HistioCure Foundation
  2. NIH R01 [CA154489]
  3. NIH SPORE in Lymphoma [P50CA126752]
  4. St. Baldrick's Consortium Grant for the North American Consortium for Histiocytosis Research
  5. Histiocytosis Research Trust (UK)
  6. Leventis Foundation
  7. Histiocytosis Association
  8. Wellcome Trust [101155/Z/13/Z] Funding Source: Wellcome Trust
  9. MRC [G0800358] Funding Source: UKRI
  10. Medical Research Council [G0800358] Funding Source: researchfish
  11. Wellcome Trust [101155/Z/13/Z] Funding Source: researchfish

向作者/读者索取更多资源

Langerhans cell histiocytosis (LCH) is a heterogeneous disease characterized by common histology of inflammatory lesions containing Langerin(+) (CD207) histiocytes. Emerging data support a model in which MAPK activation in self-renewing hematopoietic progenitors may drive disseminated high-risk disease, whereas MAPK activation in more differentiated committed myeloid populations may induce low-risk LCH. The heterogeneous clinical manifestations with shared histology may represent the final common pathway of an acquired defect of differentiation, initiated at more than one point. Implications of this model include re-definition of LCH as a myeloid neoplasia and re-focusing therapeutic strategies on the cells and lineages of origin.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据